Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improved antibody targeting with interferon-alpha-2b conjugate

M L Thakur1, J Li, M Donegan

  • 1Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107, USA.

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|May 1, 1997
PubMed
Summary

Conjugating interferon-alpha-2b (IFN) with monoclonal antibodies (mAbs) significantly enhanced tumor uptake of radiolabeled mAbs in animal models. This novel approach also reduced off-target uptake in the liver and blood, improving diagnostic and therapeutic potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vapreotide labeled with Tc-99m for imaging tumors.

International journal of oncology·2011
Same author

Radiolabeled somatostatin analogs in prostate cancer.

Nuclear medicine and biology·1997
Same author

Sandostatin labeled with 99mTc: in vitro stability, in vivo validity and comparison with 111In-DTPA-octreotide.

Peptide research·1996
Same author

The ribosomal DNA loci in Plasmodium falciparum accumulate mutations independently.

Journal of molecular biology·1995
Same author

Binding of phenylarsenoxide to Arg-tRNA protein transferase is independent of vicinal thiols.

Biochemistry·1995
Same author

The oncogene qin codes for a transcriptional repressor.

Cancer research·1995

Area of Science:

  • Oncology
  • Immunology
  • Radiopharmaceuticals

Background:

  • Monoclonal antibodies (mAbs) are crucial for targeted cancer therapy and diagnostics.
  • Interferon-alpha-2b (IFN) is a biological response modifier with potential therapeutic applications.
  • Improving the specificity and reducing off-target effects of radiolabeled mAbs remains a challenge.

Purpose of the Study:

  • To investigate if conjugating interferon-alpha-2b (IFN) with specific monoclonal antibodies (mAbs) can enhance tumor uptake and reduce non-specific uptake of radiolabeled mAbs.
  • To evaluate the diagnostic and therapeutic potential of IFN-mAb conjugates in preclinical cancer models.

Main Methods:

  • Conjugation of IFN-alpha-2b with anti-melanoma (ME 31.3) and anti-colorectal carcinoma (anti-CEA F-6) mAbs.

Related Experiment Videos

  • Characterization of mAb binding affinity (Kd values).
  • Administration of IFN-mAb conjugates followed by radiolabeled mAb (Tc-99m labeled F(ab')2) in athymic nude mice bearing experimental tumors.
  • Quantification of tumor, liver, and blood uptake, and calculation of tumor-to-tissue ratios at 24 hours post-injection.

    • Main Results:

    • IFN-mAb conjugates significantly increased tumor uptake of radiolabeled mAbs in both melanoma and colorectal carcinoma models.
    • Liver uptake of radiolabeled mAbs decreased by up to 75% in melanoma models.
    • Tumor-to-muscle and tumor-to-blood ratios were significantly enhanced (200-500% and 500-1000% respectively) in both models.

    Conclusions:

    • IFN-mAb conjugates show promise in improving the tumor targeting efficiency of radiolabeled mAbs.
    • This strategy may enhance diagnostic accuracy and therapeutic efficacy by reducing off-target organ accumulation.
    • Further studies are warranted to explore the full potential of IFN-mAb conjugates in cancer imaging and therapy.